Structure-based cross-docking analysis of antibody–antigen interactions
Abstract Antibody–antigen interactions are critical to our immune response, and understanding the structure-based biophysical determinants for their binding specificity and affinity is of fundamental importance. We present a computational structure-based cross-docking study to test the identificatio...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f7fd1839aab14bafae9116c755930e14 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Abstract Antibody–antigen interactions are critical to our immune response, and understanding the structure-based biophysical determinants for their binding specificity and affinity is of fundamental importance. We present a computational structure-based cross-docking study to test the identification of native antibody–antigen interaction pairs among cognate and non-cognate complexes. We picked a dataset of 17 antibody–antigen complexes of which 11 have both bound and unbound structures available, and we generated a representative ensemble of cognate and non-cognate complexes. Using the Rosetta interface score as a classifier, the cognate pair was the top-ranked model in 80% (14/17) of the antigen targets using bound monomer structures in docking, 35% (6/17) when using unbound, and 12% (2/17) when using the homology-modeled backbones to generate the complexes. Increasing rigid-body diversity of the models using RosettaDock’s local dock routine lowers the discrimination accuracy with the cognate antibody–antigen pair ranking in bound and unbound models but recovers additional top-ranked cognate complexes when using homology models. The study is the first structure-based cross-docking attempt aimed at distinguishing antibody–antigen binders from non-binders and demonstrates the challenges to address for the methods to be widely applicable to supplement high-throughput experimental antibody sequencing workflows. |
|---|